- Home
- XBIT vs IPHA Comparison
XBIT vs IPHA Comparison
Compare XBIT & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XBIT
- IPHA
- Stock Information
- Founded
- XBIT 2005
- IPHA 1999
- Country
- XBIT United States
- IPHA France
- Employees
- XBIT N/A
- IPHA N/A
- Industry
- XBIT Pharmaceuticals and Biotechnology
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- XBIT Health Care
- IPHA Health Care
- Exchange
- XBIT Nasdaq
- IPHA Nasdaq
- Market Cap
- XBIT 194.5M
- IPHA 150.9M
- IPO Year
- XBIT 2015
- IPHA 2019
- Fundamental
- Price
- XBIT $3.40
- IPHA $1.93
- Analyst Decision
- XBIT
- IPHA Strong Buy
- Analyst Count
- XBIT 0
- IPHA 1
- Target Price
- XBIT N/A
- IPHA $11.50
- AVG Volume (30 Days)
- XBIT 52.0K
- IPHA 50.9K
- Earning Date
- XBIT 03-14-2025
- IPHA 03-20-2025
- Dividend Yield
- XBIT N/A
- IPHA N/A
- EPS Growth
- XBIT N/A
- IPHA N/A
- EPS
- XBIT N/A
- IPHA N/A
- Revenue
- XBIT N/A
- IPHA $36,202,722.00
- Revenue This Year
- XBIT N/A
- IPHA N/A
- Revenue Next Year
- XBIT N/A
- IPHA $101.65
- P/E Ratio
- XBIT N/A
- IPHA N/A
- Revenue Growth
- XBIT N/A
- IPHA N/A
- 52 Week Low
- XBIT $3.25
- IPHA $1.29
- 52 Week High
- XBIT $9.96
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- XBIT 26.88
- IPHA 56.50
- Support Level
- XBIT $3.40
- IPHA $1.72
- Resistance Level
- XBIT $3.69
- IPHA $1.92
- Average True Range (ATR)
- XBIT 0.20
- IPHA 0.10
- MACD
- XBIT 0.05
- IPHA 0.02
- Stochastic Oscillator
- XBIT 3.85
- IPHA 100.00
About XBIT XBiotech Inc.
XBiotech Inc is a United States-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-IL-1 a therapeutic antibody as a treatment for cancer. Geographically, all of its operations are in the United States.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.